Stocksigma LogoStocksigma Logo

Dr. Reddy’s Reports Q2 FY27 Financial Results

Dr. Reddy’s posted Q2 FY27 revenue of ₹8,671 Cr, down 1.5% YoY but up 7% QoQ, impacted by lower lenalidomide sales despite double-digit base business

Dr. Reddy’s Reports Q2 FY27 Financial Results

Dr Reddys Laboratories Ltd · Investor Presentation · 23 Oct 2026, 11:07 pm

Dr. Reddy’s Reports Q2 FY27 Financial Results Dr. Reddy’s posted Q2 FY27 revenue of ₹8,671 Cr, down 1.5% YoY but up 7% QoQ, impacted by lower lenalidomide sales despite double-digit base business growth. EBITDA fell 24% YoY to ₹1,783 Cr (20.6% margin), while PAT declined 36% YoY to ₹925 Cr. Segmentally, Global Generics stood at ₹7,793 Cr, driven by Emerging Markets (+24% YoY) and India (+17% YoY), offsetting North America (-23% YoY). Aurigene CDMO crossed $100+ million annual revenue. Net cash surplus closed at ₹2,502 Cr as of 30th Sep'26.

Original exchange filing (PDF)

More announcements from Dr Reddys Laboratories Ltd

All Dr Reddys Laboratories Ltd announcements